Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Perspective Therapeutics Inc CATX

Healthcare Biotechnology
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. It is also developing imaging diagnostics that... see more

Recent & Breaking News (NYSEAM:CATX)

Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire May 24, 2024

Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024

GlobeNewswire May 20, 2024

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results

GlobeNewswire May 15, 2024

Perspective Therapeutics to Participate at Upcoming May Investor Conferences

GlobeNewswire May 3, 2024

Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results

GlobeNewswire May 2, 2024

Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs

GlobeNewswire April 30, 2024

Perspective Therapeutics to Participate at Upcoming April Investor Conferences

GlobeNewswire April 8, 2024

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results

GlobeNewswire March 28, 2024

Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma

GlobeNewswire March 18, 2024

Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024

GlobeNewswire March 11, 2024

Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility

GlobeNewswire March 5, 2024

Perspective Therapeutics Announces $87.4 Million Private Placement

GlobeNewswire March 4, 2024

Perspective Therapeutics to Participate at Upcoming Investor Conferences

GlobeNewswire February 26, 2024

Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

GlobeNewswire February 12, 2024

Perspective Therapeutics Introduces "Pre-Targeting" Theranostic Technology Platform

GlobeNewswire February 1, 2024

Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement

GlobeNewswire January 22, 2024

Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement

GlobeNewswire January 18, 2024

Perspective Therapeutics Announces Proposed Public Offering

GlobeNewswire January 17, 2024

Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT-α-NET and [(212)Pb]VMT01

GlobeNewswire January 17, 2024

Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics

GlobeNewswire January 9, 2024